ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

September 30, 2012

Conditions
Coronary Occlusions
Interventions
DEVICE

Cypher sirolimus eluting coronary stent

Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.

Trial Locations (16)

10032

New York Presbyterian Medical, New York

20010

Washington Hospital Center, Washington D.C.

27710

Duke University Medical Center, Durham

28203

The Sanger Clinic PA, Charlotte

30322

Emory University, Atlanta

44035

North Ohio Heart Center, Elyria

48073

William Beaumont Hospital, Royal Oak

64111

Saint Lukes Hospital, Kansas City

78756

Heart Hospital of Austin, Austin

92037

Green Hospital of Scripps Health, La Jolla

Scripps Memorial Hospital-La Jolla, La Jolla

02115

Brigham and Womens Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

V5Z 1M9

Vancouver Hospital and Health Science Centre, Vancouver

M5B 1W8

Saint Michaels Hospital, Toronto

M5G 2C4

Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cordis Corporation

INDUSTRY

lead

Sunil Rao

OTHER

NCT00378612 - ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial | Biotech Hunter | Biotech Hunter